Corcept Therapeutics Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Corcept Therapeutics Inc has an operating margin of 20.3%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 22.2% the prior year.
Corcept Therapeutics Inc's revenue surged 39.9% year-over-year to $675.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Corcept Therapeutics Inc carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.35, Corcept Therapeutics Inc holds $3.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Corcept Therapeutics Inc converts 29.0% of revenue into free cash flow ($195.9M). This strong cash generation earns a score of 100/100.
Corcept Therapeutics Inc earns a strong 20.8% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 83/100. This is down from 20.9% the prior year.
Corcept Therapeutics Inc scores 18.39, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.2B) relative to total liabilities ($161.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Corcept Therapeutics Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Corcept Therapeutics Inc generates $1.40 in operating cash flow ($198.1M OCF vs $141.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
This page shows Corcept Therapeutics Inc (CORT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 25 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Corcept Therapeutics Inc generated $675.0M in revenue in fiscal year 2024. This represents an increase of 39.9% from the prior year.
Corcept Therapeutics Inc's EBITDA was $137.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.2% from the prior year.
Corcept Therapeutics Inc generated $195.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 54.4% from the prior year.
Corcept Therapeutics Inc reported $141.2M in net income in fiscal year 2024. This represents an increase of 33.0% from the prior year.
Corcept Therapeutics Inc earned $1.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 30.9% from the prior year.
Corcept Therapeutics Inc held $127.7M in cash against $0 in long-term debt as of fiscal year 2024.
Corcept Therapeutics Inc had 105M shares outstanding in fiscal year 2024. This represents an increase of 1.5% from the prior year.
Corcept Therapeutics Inc's gross margin was 98.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.
Corcept Therapeutics Inc's operating margin was 20.3% in fiscal year 2024, reflecting core business profitability. This is down 1.9 percentage points from the prior year.
Corcept Therapeutics Inc's net profit margin was 20.9% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1.1 percentage points from the prior year.
Corcept Therapeutics Inc's ROE was 20.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 0.2 percentage points from the prior year.
Corcept Therapeutics Inc invested $246.9M in research and development in fiscal year 2024. This represents an increase of 33.9% from the prior year.
Corcept Therapeutics Inc spent $15.7M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
Corcept Therapeutics Inc invested $2.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1462.6% from the prior year.
CORT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $207.6M+6.8% | $194.4M+23.7% | $157.2M-13.6% | $181.9M+11.0% | $163.8M+11.6% | $146.8M+8.4% | $135.4M+9.6% | $123.6M |
| Cost of Revenue | $4.6M+33.9% | $3.4M+42.9% | $2.4M-18.7% | $3.0M+17.1% | $2.5M-0.4% | $2.5M+35.1% | $1.9M+14.0% | $1.6M |
| Gross Profit | $203.0M+6.3% | $191.0M+23.4% | $154.8M-13.5% | $178.9M+11.0% | $161.3M+11.8% | $144.3M+8.0% | $133.5M+9.5% | $122.0M |
| R&D Expenses | $68.8M+13.8% | $60.5M-0.4% | $60.7M-13.6% | $70.3M+19.7% | $58.7M+0.4% | $58.5M+6.9% | $54.7M+20.2% | $45.5M |
| SG&A Expenses | $124.0M+19.4% | $103.9M+14.5% | $90.7M+8.7% | $83.4M+24.6% | $66.9M+19.0% | $56.3M+19.3% | $47.2M+4.2% | $45.3M |
| Operating Income | $10.2M-61.7% | $26.7M+680.9% | $3.4M-86.5% | $25.3M-29.0% | $35.6M+20.7% | $29.5M-6.8% | $31.7M+1.6% | $31.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$4.4M-28.0% | -$3.5M+68.4% | -$10.9M-999.5% | $1.2M-80.1% | $6.1M-15.5% | $7.2M+32.6% | $5.5M+8.9% | $5.0M |
| Net Income | $19.7M-44.0% | $35.1M+71.1% | $20.5M-33.2% | $30.7M-13.4% | $35.5M+27.8% | $27.8M-11.5% | $31.4M-0.1% | $31.4M |
| EPS (Diluted) | $0.16-44.8% | $0.29+70.6% | $0.17-32.0% | $0.25-21.9% | $0.32+28.0% | $0.25-7.4% | $0.27-3.6% | $0.28 |
CORT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $823.6M+2.7% | $801.7M-5.3% | $846.5M+0.7% | $840.6M+17.6% | $714.6M+8.9% | $655.9M+5.5% | $621.5M+4.6% | $594.0M |
| Current Assets | $541.1M+22.1% | $443.1M+1.1% | $438.5M-7.0% | $471.6M-15.9% | $560.8M+11.4% | $503.4M+9.8% | $458.6M+6.3% | $431.5M |
| Cash & Equivalents | $125.1M+21.8% | $102.7M+14.4% | $89.8M-29.6% | $127.7M-0.7% | $128.6M-14.1% | $149.8M+10.5% | $135.6M+21.2% | $111.8M |
| Inventory | $12.3M+0.6% | $12.3M-14.6% | $14.4M+15.8% | $12.4M+48.6% | $8.3M+16.1% | $7.2M-7.0% | $7.7M+2.9% | $7.5M |
| Accounts Receivable | $69.6M+7.8% | $64.6M+4.4% | $61.8M+14.5% | $54.0M+0.3% | $53.8M-12.5% | $61.5M+49.6% | $41.1M+18.8% | $34.6M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $191.7M+15.5% | $165.9M+1.7% | $163.2M+1.4% | $161.0M+36.1% | $118.3M+9.5% | $108.1M-5.9% | $114.8M-13.2% | $132.3M |
| Current Liabilities | $172.3M+19.1% | $144.7M+1.1% | $143.1M+1.6% | $140.8M+39.7% | $100.8M+3.7% | $97.2M-7.0% | $104.5M-14.3% | $121.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $631.9M-0.6% | $635.8M-7.0% | $683.3M+0.5% | $679.6M+14.0% | $596.2M+8.8% | $547.9M+8.1% | $506.7M+9.8% | $461.7M |
| Retained Earnings | $619.1M+3.3% | $599.4M+6.2% | $564.3M+3.8% | $543.7M+16.7% | $465.8M+8.2% | $430.3M+6.9% | $402.5M+8.4% | $371.2M |
CORT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $54.5M+24.0% | $43.9M+756.8% | $5.1M-91.4% | $59.8M+45.3% | $41.2M+73.4% | $23.8M+303.5% | $5.9M-88.9% | $52.9M |
| Capital Expenditures | $0-100.0% | $57K-45.2% | $104K-14.0% | $121K-70.9% | $416K | $0 | $0-100.0% | $37K |
| Free Cash Flow | $54.5M+24.2% | $43.9M+773.4% | $5.0M-91.6% | $59.7M+46.4% | $40.8M+71.6% | $23.8M+303.5% | $5.9M-88.9% | $52.9M |
| Investing Cash Flow | $14.6M-79.1% | $70.1M+2311.5% | -$3.2M+95.1% | -$64.4M-6.9% | -$60.2M-567.8% | -$9.0M-152.7% | $17.1M+115.6% | -$109.6M |
| Financing Cash Flow | -$46.4M+54.9% | -$102.9M-158.6% | -$39.8M-772.1% | -$4.6M-112.3% | -$2.1M-295.9% | -$543K-170.9% | $766K+119.6% | -$3.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $42.5M-58.8% | $103.0M+275.5% | $27.4M | $0-100.0% | $3.5M+630.7% | $476K | $0 | $0 |
CORT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8%-0.4pp | 98.2%-0.2pp | 98.5%+0.1pp | 98.4%-0.1pp | 98.5%+0.2pp | 98.3%-0.3pp | 98.6%-0.1pp | 98.7% |
| Operating Margin | 4.9%-8.8pp | 13.7%+11.5pp | 2.2%-11.7pp | 13.9%-7.8pp | 21.7%+1.6pp | 20.1%-3.3pp | 23.4%-1.8pp | 25.2% |
| Net Margin | 9.5%-8.6pp | 18.1%+5.0pp | 13.1%-3.8pp | 16.9%-4.8pp | 21.7%+2.8pp | 18.9%-4.3pp | 23.2%-2.2pp | 25.4% |
| Return on Equity | 3.1%-2.4pp | 5.5%+2.5pp | 3.0%-1.5pp | 4.5%-1.4pp | 5.9%+0.9pp | 5.1%-1.1pp | 6.2%-0.6pp | 6.8% |
| Return on Assets | 2.4%-2.0pp | 4.4%+1.9pp | 2.4%-1.2pp | 3.7%-1.3pp | 5.0%+0.7pp | 4.2%-0.8pp | 5.0%-0.2pp | 5.3% |
| Current Ratio | 3.14+0.1 | 3.060.0 | 3.06-0.3 | 3.35-2.2 | 5.57+0.4 | 5.18+0.8 | 4.39+0.8 | 3.54 |
| Debt-to-Equity | 0.30+0.0 | 0.26+0.0 | 0.240.0 | 0.24+0.0 | 0.200.0 | 0.20-0.0 | 0.23-0.1 | 0.29 |
| FCF Margin | 26.2%+3.7pp | 22.6%+19.4pp | 3.2%-29.6pp | 32.8%+7.9pp | 24.9%+8.7pp | 16.2%+11.8pp | 4.3%-38.4pp | 42.8% |
Similar Companies
Frequently Asked Questions
What is Corcept Therapeutics Inc's annual revenue?
Corcept Therapeutics Inc (CORT) reported $675.0M in total revenue for fiscal year 2024. This represents a 39.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Corcept Therapeutics Inc's revenue growing?
Corcept Therapeutics Inc (CORT) revenue grew by 39.9% year-over-year, from $482.4M to $675.0M in fiscal year 2024.
Is Corcept Therapeutics Inc profitable?
Yes, Corcept Therapeutics Inc (CORT) reported a net income of $141.2M in fiscal year 2024, with a net profit margin of 20.9%.
What is Corcept Therapeutics Inc's earnings per share (EPS)?
Corcept Therapeutics Inc (CORT) reported diluted earnings per share of $1.23 for fiscal year 2024. This represents a 30.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Corcept Therapeutics Inc's EBITDA?
Corcept Therapeutics Inc (CORT) had EBITDA of $137.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Corcept Therapeutics Inc's gross margin?
Corcept Therapeutics Inc (CORT) had a gross margin of 98.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Corcept Therapeutics Inc's operating margin?
Corcept Therapeutics Inc (CORT) had an operating margin of 20.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Corcept Therapeutics Inc's net profit margin?
Corcept Therapeutics Inc (CORT) had a net profit margin of 20.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Corcept Therapeutics Inc's return on equity (ROE)?
Corcept Therapeutics Inc (CORT) has a return on equity of 20.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Corcept Therapeutics Inc's free cash flow?
Corcept Therapeutics Inc (CORT) generated $195.9M in free cash flow during fiscal year 2024. This represents a 54.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Corcept Therapeutics Inc's operating cash flow?
Corcept Therapeutics Inc (CORT) generated $198.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Corcept Therapeutics Inc's total assets?
Corcept Therapeutics Inc (CORT) had $840.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Corcept Therapeutics Inc's capital expenditures?
Corcept Therapeutics Inc (CORT) invested $2.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Corcept Therapeutics Inc spend on research and development?
Corcept Therapeutics Inc (CORT) invested $246.9M in research and development during fiscal year 2024.
Does Corcept Therapeutics Inc buy back shares?
Yes, Corcept Therapeutics Inc (CORT) spent $15.7M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Corcept Therapeutics Inc have outstanding?
Corcept Therapeutics Inc (CORT) had 105M shares outstanding as of fiscal year 2024.
What is Corcept Therapeutics Inc's current ratio?
Corcept Therapeutics Inc (CORT) had a current ratio of 3.35 as of fiscal year 2024, which is generally considered healthy.
What is Corcept Therapeutics Inc's debt-to-equity ratio?
Corcept Therapeutics Inc (CORT) had a debt-to-equity ratio of 0.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Corcept Therapeutics Inc's return on assets (ROA)?
Corcept Therapeutics Inc (CORT) had a return on assets of 16.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Corcept Therapeutics Inc's Altman Z-Score?
Corcept Therapeutics Inc (CORT) has an Altman Z-Score of 18.39, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Corcept Therapeutics Inc's Piotroski F-Score?
Corcept Therapeutics Inc (CORT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Corcept Therapeutics Inc's earnings high quality?
Corcept Therapeutics Inc (CORT) has an earnings quality ratio of 1.40x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Corcept Therapeutics Inc?
Corcept Therapeutics Inc (CORT) scores 97 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.